Loading
A phase 2 trial of Calderasib, Pembrolizumab, Cetuximab and Sacituzumab tirumotecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) is a phase 2 interventional study registered as NCT07252739 by Merck Sharp & Dohme LLC, with 140 participants planned, started 2025-12-19 and due to reach its primary completion in 2029-11-15. Interventions recorded: MK-1084, Pembrolizumab, Cetuximab, Sacituzumab tirumotecan (sac-TMT) and Rescue medication.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Calderasib, Sacituzumab tirumotecan, Cetuximab, Merck & Co. (MSD) and the tag pipeline.
Shares Calderasib, Cetuximab, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/